Zacks Investment Research upgraded shares of Electromed, Inc. (NYSEMKT:ELMD) from a sell rating to a hold rating in a report released on Thursday morning.

According to Zacks, “Electromed, Inc. manufactures, markets and sells products that provide airway clearance therapy to patients with compromised pulmonary function. The Company is the designer, manufacturer and worldwide provider of the SmartVest┬« Airway Clearance System and related products. The patented system uses High Frequency Chest Wall Oscillation (HFCWO), an alternative to Chest Physiotherapy (CPT), to deliver airway clearance treatment. The Company manufactures its products for use by chronically-ill patients who face health risks due to pneumonia and mucus accumulation in the lungs, particularly patients with cystic fibrosis, chronic obstructive pulmonary disease (COPD), bronchiectasis, and neuro-muscular disorders. The purpose of its primary product, the SmartVest System, is to loosen, mobilize, and release respiratory secretions from the lungs. The Company’s products are primarily used in the home health care market and in hospitals. Electromed, Inc. is headquartered in New Prague, Minnesota. “

Separately, TheStreet upgraded Electromed from a hold rating to a buy rating in a report on Friday, September 16th.

Shares of Electromed (NYSEMKT:ELMD) opened at 4.04 on Thursday. The stock has a market capitalization of $33.20 million, a P/E ratio of 16.22 and a beta of 0.89. Electromed has a 12-month low of $1.55 and a 12-month high of $6.26. The firm’s 50-day moving average is $4.18 and its 200 day moving average is $4.36.

Electromed (NYSEMKT:ELMD) last posted its quarterly earnings results on Tuesday, November 8th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by $0.01. The firm earned $5.50 million during the quarter, compared to analysts’ expectations of $5.90 million. On average, equities research analysts forecast that Electromed will post $0.13 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Electromed, Inc. (ELMD) Upgraded at Zacks Investment Research” was first published by Daily Political and is the sole property of of Daily Political. If you are reading this report on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this report can be viewed at

In other news, Director William Eckles purchased 20,000 shares of the business’s stock in a transaction on Thursday, November 10th. The stock was acquired at an average cost of $3.61 per share, for a total transaction of $72,200.00. Following the purchase, the director now directly owns 13,072 shares in the company, valued at approximately $47,189.92. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Several large investors have recently added to or reduced their stakes in the stock. KCG Holdings Inc. purchased a new stake in Electromed during the third quarter worth about $343,000. Spark Investment Management LLC increased its position in shares of Electromed by 170.1% in the third quarter. Spark Investment Management LLC now owns 41,600 shares of the company’s stock worth $190,000 after buying an additional 26,200 shares during the period. Municipal Employees Retirement System of Michigan bought a new position in shares of Electromed during the third quarter worth about $323,000. Alambic Investment Management L.P. increased its position in shares of Electromed by 13.4% in the third quarter. Alambic Investment Management L.P. now owns 33,520 shares of the company’s stock worth $154,000 after buying an additional 3,949 shares during the period. Finally, Creative Planning increased its position in shares of Electromed by 3.0% in the third quarter. Creative Planning now owns 34,000 shares of the company’s stock worth $156,000 after buying an additional 1,000 shares during the period.

Electromed Company Profile

Electromed, Inc develops, manufactures and markets airway clearance products, which apply High Frequency Chest Wall Oscillation (HFCWO) therapy in pulmonary care for patients of all ages. The Company’s products include the SmartVest Airway Clearance System (SmartVest System), the SmartVest SQL System and others.

Get a free copy of the Zacks research report on Electromed (ELMD)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Electromed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Electromed Inc. and related companies with's FREE daily email newsletter.